April 10, 2018; 90 (15 Supplement) April 27, 2018
EVOLVE-MS-1: A Phase 3, Open-Label, Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis (P6.360)
Robert Naismith, Richard Leigh-Pemberton, David Rezendes, Narinder Nangia, Boris Kandinov, Lisa von Moltke, Jerry Wolinsky
First published April 9, 2018,
Robert Naismith
1Washington University School of Medicine St Louis MO United States
Richard Leigh-Pemberton
2Alkermes Waltham MA United States
David Rezendes
2Alkermes Waltham MA United States
Narinder Nangia
2Alkermes Waltham MA United States
Boris Kandinov
2Alkermes Waltham MA United States
Lisa von Moltke
2Alkermes Waltham MA United States
Jerry Wolinsky
3McGovern Medical School, The University of Texas Health Science Center at Houston Houston TX United States
EVOLVE-MS-1: A Phase 3, Open-Label, Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis (P6.360)
Robert Naismith, Richard Leigh-Pemberton, David Rezendes, Narinder Nangia, Boris Kandinov, Lisa von Moltke, Jerry Wolinsky
Neurology Apr 2018, 90 (15 Supplement) P6.360;
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 90 no. 15 Supplement P6.360
Print ISSN:
Online ISSN:
History:
- First Published April 9, 2018.
Copyright & Usage:
© 2018
Author Disclosures
Article usage
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.